Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)

Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa) Meeting Abstract

sustainable development goals

SDG 03: Good Health and Well-being

publication date

June 1, 2021

webpage

Web of Science

published in

EUROPEAN UROLOGY Journal

start page

S1180

end page

S1181

volume

79